Program
ivarmacitinib
Also written as “SHR0302”, “SHR0302 Tablets” and “SHR0302 Base Gel”.
Its studies are mostly in Arthritis, Rheumatoid · Vitiligo · Alopecia Areata · Colitis, Ulcerative · Dermatitis, Atopic, led by Jiangsu HengRui Medicine.
Drug pageIvarmacitinib: every studyAll 43 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 254 open or running | phase 3since Apr 2, 2020 | Apr 7, 2015 | Mar 2027phase 2 · NCT07251595 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Apr 7, 2015.
- Jul 15, 2020Phase 3 study in Spondylitis, AnkylosingNCT04481139 · 504 enrolled · China
- Jan 11, 2021Phase 1 study in Healthy SubjectsNCT04712838 · 24 enrolled · China
- Feb 24, 2021Phase 3 study in VitiligoNCT04774809 · 75 enrolled · China
- May 1, 2021Phase 3 study in Dermatitis, AtopicNCT04875169 · 336 enrolled · Canada, China
- Sep 8, 2021Phase 1 study in Arthritis, RheumatoidNCT05047341 · 6 enrolled · China
- Dec 10, 2021Phase 3 study in Colitis, UlcerativeNCT05181137 · 368 planned · United States, China, Georgia and more
- Jan 25, 2022Named ivarmacitinibINNProposed as its International Nonproprietary Name in WHO's List 126 · before, SHR0302
- Apr 6, 2022Phase 3 study in Non-Radiographic Axial SpondyloarthritisNCT05324631 · 300 enrolled · China
- May 23, 20222 phase 1 studies in Arthritis, RheumatoidNCT05392127, NCT05404724
- Jul 20, 2022Phase 3 study in Alopecia AreataNCT05470413 · 330 enrolled · China
- May 4, 2023Phase 1 study in Graft vs Host DiseaseNCT05856058 · 16 enrolled · China
- Jan 1, 2024Phase 1 study in Autoimmune DiseasesNCT06202612 · 16 enrolled · China
- Jan 20, 2025Phase 2 study in VitiligoNCT06790862 · 155 enrolled · China
- Jul 27, 2025Phase 1 study in Preoperative Sedation of AdultsNCT07098117 · 32 enrolled · China
- Nov 19, 2025Phase 2 study in Non-segmental VitiligoNCT07251595 · 176 planned · China
Ahead
- Mar 2027Primary completion: phase 2 study in Non-segmental VitiligoNCT07251595
TargetBeta
“The sulfate salt form of ivarmacitinib, an orally available inhibitor of Janus-associated kinase 1 (JAK1), ”NCIt, by rule
Other programs on JAK1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| baricitinibrule | Eli Lilly | phase 4 | 59 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 31 |
| abrocitinibrule | Pfizer | phase 3 | 30 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| momelotinibrule | GlaxoSmithKline | phase 3 | 17 |
| golidocitinibrule | Dizal Pharmaceuticals | phase 3 | 10 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07251595Non-segmental Vitiligo · China | 2 | Recruiting | Mar 2027 | 176 |
| NCT07098117Preoperative Sedation of Adults · China | 1 | Completed | Jul 31, 2024 | 32 |
| NCT06790862Vitiligo · China | 2 | Active, not recruiting | Mar 3, 2026 | 155 |
| NCT06202612Autoimmune Diseases · China | 1 | Completed | Feb 21, 2024 | 16 |
| NCT05856058Graft vs Host Disease · China | 1 | Completed | Jul 3, 2023 | 16 |
| NCT05470413Alopecia Areata · China | 3 | Active, not recruiting | Oct 31, 2023 | 330 |
| NCT05404724Arthritis, Rheumatoid · China | 1 | Completed | Jul 11, 2022 | 14 |
| NCT05392127Arthritis, Rheumatoid · China | 1 | Completed | Aug 18, 2022 | 24 |
| NCT05324631Non-Radiographic Axial Spondyloarthritis · China | 3 | UNKNOWN | Aug 30, 2024 | 300 |
| NCT05181137Colitis, Ulcerative · United States, China, Georgia and more | 3 | Recruiting | Oct 31, 2024 | 368 |
| NCT05047341Arthritis, Rheumatoid · China | 1 | Completed | Sep 19, 2021 | 6 |
| NCT04875169Dermatitis, Atopic · Canada, China | 3 | Completed | Aug 12, 2022 | 336 |
| NCT04774809Vitiligo · China | 3 | Terminated | Mar 21, 2022 | 75 |
| NCT04712838Healthy Subjects · China | 1 | Completed | Apr 13, 2021 | 24 |
| NCT04481139Spondylitis, Ankylosing · China | 3 | Completed | Nov 15, 2022 | 504 |
| NCT04333771Arthritis, Rheumatoid · China | 3 | Completed | Jan 30, 2023 | 566 |
| NCT04293029Hepatic Impairment · China | 1 | Completed | Dec 27, 2020 | 24 |
| NCT04346316Alopecia Areata · United States, Australia, China | 2 | Completed | Jun 10, 2021 | 94 |
| NCT04162899Dermatitis, Atopic · China | 2 | Completed | Aug 21, 2020 | 105 |
| NCT03677648Crohn Disease · United States, China, Poland and more | 2 | Completed | Sep 16, 2021 | 112 |
| NCT03675477Colitis, Ulcerative · United States, China, Poland and more | 2 | Completed | Nov 30, 2020 | 164 |
| NCT03254966Arthritis, Rheumatoid · China | 2 | Completed | Apr 16, 2019 | 194 |
| NCT02892370Arthritis, Rheumatoid · China | 1 | UNKNOWN | Sep 2016 | 14 |
| NCT02665910Arthritis, Rheumatoid · China | 1 | UNKNOWN | Dec 2016 | 48 |
| NCT02423538Arthritis, Rheumatoid · China | 1 | UNKNOWN | Jul 2016 | 64 |
How it is read
Names in the registry
- “SHR0302”, 21 entries
- “SHR0302 Tablets”, 2 entries
- “SHR0302 Base Gel”, 2 entries
- “SHR0302Base gel”, 1 entry
- “SHR0302 quick release tablets”, 1 entry
Codes read as this program: SHR0302.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 8 studies
- Vitiligo, 3 studies
- Alopecia Areata, 2 studies
- Colitis, Ulcerative, 2 studies
- Dermatitis, Atopic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.